Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model

Yuan, Quan; Xing, Kailin; Zhang, Lanlin; Zhao, Fangyu; Yao, Ming; Hu, Aiqun; Wu, Xianghua

doi:10.1007/s00432-018-2720-7

Cited by 2 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Active vaccination using MeV vaccine not only protected mice from developing tumors, but also eradicated established tumors. In addition, measles vaccine decreased the population of myeloid derived suppressor cells and regulatory T cells ( 128 ).…”

Section: Measles Vaccinementioning

confidence: 99%

Repurposing Infectious Diseases Vaccines Against Cancer

et al. 2021

View full text Add to dashboard Cite

Vaccines used to prevent infections have long been known to stimulate immune responses to cancer as illustrated by the approval of the Bacillus Calmette–Guérin (BCG) vaccine to treat bladder cancer since the 1970s. The recent approval of immunotherapies has rejuvenated this research area with reports of anti-tumor responses with existing infectious diseases vaccines used as such, either alone or in combination with immune checkpoint inhibitors. Here, we have reviewed and summarized research activities using approved vaccines to treat cancer. Data supporting a cancer therapeutic use was found for 16 vaccines. For 10 (BCG, diphtheria, tetanus, human papillomavirus, influenza, measles, pneumococcus, smallpox, typhoid and varicella-zoster), clinical trials have been conducted or are ongoing. Within the remaining 6, preclinical evidence supports further evaluation of the rotavirus, yellow fever and pertussis vaccine in carefully designed clinical trials. The mechanistic evidence for the cholera vaccine, combined with the observational data in colorectal cancer, is also supportive of clinical translation. There is limited data for the hepatitis B and mumps vaccine (without measles vaccine). Four findings are worth highlighting: the superiority of intravesical typhoid vaccine instillations over BCG in a preclinical bladder cancer model, which is now the subject of a phase I trial; the perioperative use of the influenza vaccine to limit and prevent the natural killer cell dysfunction induced by cancer surgery; objective responses following intratumoral injections of measles vaccine in cutaneous T-cell lymphoma; objective responses induced by human papillomavirus vaccine in cutaneous squamous cell carcinoma. All vaccines are intended to induce or improve an anti-tumor (immune) response. In addition to the biological and immunological mechanisms that vary between vaccines, the mode of administration and sequence with other (immuno-)therapies warrant more attention in future research.

show abstract

Section: Measles Vaccinementioning

confidence: 99%

Repurposing Infectious Diseases Vaccines Against Cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…At the same time, some studies have shown that repeated intratumoral injection of OV can prolong its anti-tumor effect and induce lasting anti-tumor memory ( Ghonime et al, 2018 ). It is possible that vaccines that have been injected as OV, such as the measles virus, may also act on anti-tumor ( Qi et al, 2018 ; Leb-Reichl et al, 2021 ), but may also inhibit the anti-tumor effect ( Laksono et al, 2018 ; Rudak et al, 2021 ).…”

Section: The Process Of Treating a Tumor With An Oncolytic Virusmentioning

confidence: 99%

Development and application of oncolytic viruses as the nemesis of tumor cells

et al. 2023

View full text Add to dashboard Cite

Viruses and tumors are two pathologies that negatively impact human health, but what occurs when a virus encounters a tumor? A global consensus among cancer patients suggests that surgical resection, chemotherapy, radiotherapy, and other methods are the primary means to combat cancer. However, with the innovation and development of biomedical technology, tumor biotherapy (immunotherapy, molecular targeted therapy, gene therapy, oncolytic virus therapy, etc.) has emerged as an alternative treatment for malignant tumors. Oncolytic viruses possess numerous anti-tumor properties, such as directly lysing tumor cells, activating anti-tumor immune responses, and improving the tumor microenvironment. Compared to traditional immunotherapy, oncolytic virus therapy offers advantages including high killing efficiency, precise targeting, and minimal side effects. Although oncolytic virus (OV) therapy was introduced as a novel approach to tumor treatment in the 19th century, its efficacy was suboptimal, limiting its widespread application. However, since the U.S. Food and Drug Administration (FDA) approved the first OV therapy drug, T-VEC, in 2015, interest in OV has grown significantly. In recent years, oncolytic virus therapy has shown increasingly promising application prospects and has become a major research focus in the field of cancer treatment. This article reviews the development, classification, and research progress of oncolytic viruses, as well as their mechanisms of action, therapeutic methods, and routes of administration.

show abstract

Protective immunity elicited by measles vaccine exerts anti-tumor effects on measles virus hemagglutinin gene-modified cancer cells in a mouse model

Abstract: Our study demonstrated that tumor cells expressing H protein could activate the immune memory response against MV, which exerted specific anti-tumor effects, and indicated that the MV-H gene can be used as a potential therapeutic gene for cancer gene therapy.

Cited by 2 publications

References 27 publications

Repurposing Infectious Diseases Vaccines Against Cancer

Repurposing Infectious Diseases Vaccines Against Cancer

Development and application of oncolytic viruses as the nemesis of tumor cells

Contact Info

Product

Resources

About